CN108366988A - 包含大麻素的口服药物组合物，其制备和使用方法 - Google Patents

包含大麻素的口服药物组合物，其制备和使用方法 Download PDF

Info

Publication number
CN108366988A
CN108366988A CN201680057462.4A CN201680057462A CN108366988A CN 108366988 A CN108366988 A CN 108366988A CN 201680057462 A CN201680057462 A CN 201680057462A CN 108366988 A CN108366988 A CN 108366988A
Authority
CN
China
Prior art keywords
oil
composition
cannboid
acid
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680057462.4A
Other languages
English (en)
Chinese (zh)
Inventor
L·都纳杜齐
C·M·都纳杜齐
C·G·B·德梅内塞斯
L·B·朱尼尔
V·J·T·菲尔厚
P·M·罗萨
J·A·克里帕
J·E·C·阿拉
A·W·扎尔迪
F·S·吉马良斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prati Dunadutsi Co Ltd
Universidade de Sao Paulo USP
Original Assignee
Prati Dunadutsi Co Ltd
Universidade de Sao Paulo USP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58288018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108366988(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prati Dunadutsi Co Ltd, Universidade de Sao Paulo USP filed Critical Prati Dunadutsi Co Ltd
Publication of CN108366988A publication Critical patent/CN108366988A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201680057462.4A 2015-09-18 2016-09-16 包含大麻素的口服药物组合物，其制备和使用方法 Pending CN108366988A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
BRBR102015024165-8 2015-09-18
PCT/BR2016/050231 WO2017045053A1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Publications (1)

Publication Number Publication Date
CN108366988A true CN108366988A (zh) 2018-08-03

Family

ID=58288018

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680057462.4A Pending CN108366988A (zh) 2015-09-18 2016-09-16 包含大麻素的口服药物组合物，其制备和使用方法

Country Status (8)

Country Link
US (1) US20180264121A1 (https=)
EP (1) EP3351242A4 (https=)
JP (1) JP2018528985A (https=)
CN (1) CN108366988A (https=)
AU (1) AU2016322148A1 (https=)
BR (2) BR102015024165A2 (https=)
CA (1) CA2998739A1 (https=)
WO (1) WO2017045053A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108968071A (zh) * 2018-09-26 2018-12-11 江西中医药大学 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用
CN111603443A (zh) * 2020-06-12 2020-09-01 苏州旺山旺水生物医药有限公司 一种稳定的cbd组合物及其应用
CN113694049A (zh) * 2020-05-21 2021-11-26 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN113727704A (zh) * 2019-04-17 2021-11-30 诺狄更斯公司 大麻素锭剂制剂

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658137A4 (en) * 2017-07-27 2020-06-03 Shaaban, Basil Adil CANNABINOID COMPOSITION WITH OPTIMIZED FATTY ACID PROFILE
US20190083622A1 (en) * 2017-10-16 2019-03-21 Joshua Raderman Cannabinoid formulations and methods including the antioxidant c60
WO2019153073A1 (en) * 2018-02-07 2019-08-15 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
BR102018002843A2 (pt) 2018-02-09 2019-08-27 Prati, Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
EP3787614B1 (en) 2018-05-03 2024-07-31 SCF Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions and use thereof for modulating a microbiota composition of a subject
US20220304963A1 (en) * 2018-07-27 2022-09-29 Basil Shaaban Composition having an optimized fatty acid excipient profile
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
WO2020044118A1 (en) * 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
EP3893673A4 (en) 2018-12-14 2023-05-03 Natural Extraction Systems, LLC COMPOSITIONS AND METHODS RELATED TO ANIONIC CANNABINOID MOLECULES
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
DK3826630T3 (da) * 2019-07-21 2022-09-26 Scf Pharma Inc Sammensætninger af cannabinoider med polyumættede fedtsyremonoglycerider og anvendelser heraf
AU2020326738A1 (en) * 2019-08-08 2022-03-03 Purcann Pharma Inc. Oral formulations of cannabis extracts and methods of making same
US12419855B2 (en) 2019-08-28 2025-09-23 Natural Extraction Systems, LLC Compositions comprising cannabinoid ions that are dissolved in glycerol
EP4028059B1 (en) * 2019-09-09 2025-12-24 Cardiol Therapeutics Inc. Stable medicinal cannabidiol compositions
US12349706B2 (en) 2020-07-31 2025-07-08 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
JP7837051B2 (ja) * 2021-09-08 2026-03-30 株式会社東洋新薬 経口組成物
US20260108540A1 (en) * 2022-10-12 2026-04-23 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
EP4665718A1 (en) 2023-02-13 2025-12-24 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof
WO2025024009A1 (en) * 2023-07-24 2025-01-30 Poviva Corp. Compositions and methods for treating epilepsy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
CN104363890A (zh) * 2012-05-07 2015-02-18 回音制药公司 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
CN106999598A (zh) * 2014-05-29 2017-08-01 因塞斯制药有限公司 稳定的大麻素类化合物制剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0548238A1 (en) * 1990-09-13 1993-06-30 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20070129340A1 (en) * 2004-02-06 2007-06-07 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
PT1903866E (pt) * 2005-11-07 2016-06-09 Murty Pharmaceuticals Inc Distribuição melhorada de tetra-hidrocanabinol
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
US9763991B2 (en) * 2013-06-13 2017-09-19 Cannabis Science International Holding B.V. Composition for the treatment of neurobehavioral disorders
GB2542155B (en) * 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
CN104363890A (zh) * 2012-05-07 2015-02-18 回音制药公司 含有大麻素的颗粒物及其制备方法和含有该颗粒物的口服给药单元
CN106999598A (zh) * 2014-05-29 2017-08-01 因塞斯制药有限公司 稳定的大麻素类化合物制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREA PELLICCIA等: "TREATMENT WITH CBD IN OILY SOLUTION OF DRUG-RESISTANT PAEDIATRIC EPILEPSIES", 《IACM 3RD CONFERENCE ON CANNABINOIDS IN MEDICINE，网址：HTTP://WWW.CANNABIS-MED.ORG/MEETING/LEIDEN2005/READER.PDF》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108968071A (zh) * 2018-09-26 2018-12-11 江西中医药大学 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用
CN113727704A (zh) * 2019-04-17 2021-11-30 诺狄更斯公司 大麻素锭剂制剂
CN113694049A (zh) * 2020-05-21 2021-11-26 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN111603443A (zh) * 2020-06-12 2020-09-01 苏州旺山旺水生物医药有限公司 一种稳定的cbd组合物及其应用

Also Published As

Publication number Publication date
EP3351242A1 (en) 2018-07-25
US20180264121A1 (en) 2018-09-20
EP3351242A4 (en) 2019-05-15
BR102015024165A2 (pt) 2017-03-28
WO2017045053A1 (pt) 2017-03-23
CA2998739A1 (en) 2017-03-23
AU2016322148A1 (en) 2018-04-12
BR112018005423B1 (pt) 2020-06-23
JP2018528985A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
CN108366988A (zh) 包含大麻素的口服药物组合物，其制备和使用方法
Stella et al. Cannabinoid formulations and delivery systems: current and future options to treat pain
AU2024266845B2 (en) Stable cannabinoid formulations
JP5399898B2 (ja) 神経因性疼痛の治療用カンナビノイド
JP2025118786A (ja) 安定なカンナビノイド製剤
US12544389B2 (en) Stable cannabinoid formulations
JP2023507472A (ja) カンナビノイド経口製剤
CN111787910A (zh) 包含大麻素和泊洛沙姆的口服药物制剂
US20160271252A1 (en) Stable cannabinoid formulations
CN109952098A (zh) 大麻素的自乳化组合物
WO2011133980A1 (en) Therapeutic formulation for reduced drug side effects
WO2023100138A1 (en) Oral cannabinoid compositions and methods for treating neurological diseases and disorders
El-Marasy et al. Anti-depressant effect of Naringenin-loaded hybridized nanoparticles in diabetic rats via PPARγ/NLRP3 pathway
US12178797B2 (en) Formulation for pain management
KR102445087B1 (ko) 통증 관리용 제형
WO2022027053A1 (en) Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
RU2795027C2 (ru) Фармацевтический препарат
US20220031635A1 (en) Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
WO2026061591A1 (en) Capsules with self-emulsifying drug delivery systems
WO2026061592A1 (en) Dosage forms for delivery of self-emulsifying drug delivery systems
BR102017020661A2 (pt) Forma farmacêutica, composição farmacêutica e seu uso

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180803

RJ01 Rejection of invention patent application after publication